UPDATE: Berlin Heals Holding AG has just announced the appointment of Rob ten Hoedt as the new Chairman of the Board of Directors. This pivotal move, confirmed earlier today from Zug, Switzerland, positions the company for a groundbreaking year ahead in the fight against Heart Failure.
In a statement, Marko Bagaric, Co-founder and Board Member, expressed excitement about ten Hoedt’s extensive experience in the medical technology sector, stating, “We are thrilled to welcome someone of Rob ten Hoedt’s caliber to the Board. His global impact on healthcare systems will give us even more momentum.” With over 30 years of leadership, ten Hoedt brings invaluable expertise from his previous role as Executive Vice President at Medtronic and senior positions at other leading medical firms.
Ten Hoedt shared his enthusiasm, saying, “I am very excited to join the Board of Directors at Berlin Heals Holding AG and to contribute to its revolutionary new therapy in Heart Failure. Together, we will strive to bring the life-changing benefits of the C-MIC device to patients worldwide.” His commitment signals a new chapter for the company as it aims to innovate in cardiac care.
The C-MIC Therapy, a fully implantable device, is designed to treat Heart Failure by delivering constant microcurrent to the heart, reducing inflammation and improving cardiac function. This advancement comes at a critical time when Heart Failure is escalating into a global crisis, currently affecting over 64 million people worldwide. The condition, marked by symptoms such as shortness of breath and fatigue, is projected to cost healthcare systems an astonishing $858 billion annually by 2050.
As the company prepares for an exciting year ahead, John Brumfield, CEO of Berlin Heals, remarked, “His knowledge and genuine passion for innovation will play an instrumental role in shaping our strategy.” This leadership change not only strengthens Berlin Heals but also enhances its mission to deliver effective treatments that can dramatically improve patient outcomes.
The urgency surrounding Heart Failure treatment is palpable, as it is a leading cause of death and impacts daily life for millions. With no commercially available cure, the advancements being made by Berlin Heals and the leadership of ten Hoedt could shift the tide in how this disease is managed.
Next, all eyes will be on Berlin Heals as they unveil their strategies for the upcoming year under ten Hoedt’s guidance. This is a critical moment for the company and the healthcare industry at large, as they strive to bring innovative solutions to a pressing global health issue.
Stay tuned for more updates as Berlin Heals moves forward in this urgent initiative.
